Literature DB >> 2552718

The effects of enalapril on hypertension and quality of life. A large multicenter study in Belgium.

P A de Lame1, A M Droussin, M Thomson, L Verhaest, S Wallace.   

Abstract

Belgian general practitioners studied the effect of enalapril over a period of 6 months on hypertension and quality of life in 4988 patients, whose hypertensive condition remained uncontrolled by previous treatments and/or in whom this previous drug regimen was not tolerated. Blood pressure was reduced from an average of 170/101 mm Hg at the onset of the trial to 145/85.5 mm Hg after 24 weeks. The treatment with enalapril was well tolerated and tolerance improved remarkably in the patients, whose previous treatment had caused intolerance. Quality of life, determined by means of the Nottingham Health Profile questionnaire, was favourably influenced in the patients participating in this study.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2552718

Source DB:  PubMed          Journal:  Acta Cardiol        ISSN: 0001-5385            Impact factor:   1.718


  5 in total

Review 1.  Enalapril: a review of quality-of-life and pharmacoeconomic aspects of its use in heart failure and mild to moderate hypertension.

Authors:  M I Wilde; H M Bryson; K L Goa
Journal:  Pharmacoeconomics       Date:  1994-08       Impact factor: 4.981

Review 2.  Quality of life as a therapeutic end-point. An analysis of therapeutic trials in hypertension.

Authors:  N K Hollenberg; M Testa; G H Williams
Journal:  Drug Saf       Date:  1991 Mar-Apr       Impact factor: 5.606

3.  Validating the SF-36 health survey questionnaire: new outcome measure for primary care.

Authors:  J E Brazier; R Harper; N M Jones; A O'Cathain; K J Thomas; T Usherwood; L Westlake
Journal:  BMJ       Date:  1992-07-18

Review 4.  Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension.

Authors:  P A Todd; K L Goa
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

Review 5.  Epidemiology of stroke. Importance of preventive pharmacological strategies in elderly patients and associated costs.

Authors:  I Kawachi
Journal:  Drugs Aging       Date:  1994-10       Impact factor: 3.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.